Back to top

The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk

Read MoreHide Full Article

For Immediate Release

Chicago, IL – September 14, 2017 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Apple (Nasdaq:(AAPL - Free Report)  Free Report), Pfizer (NYSE:(PFE - Free Report)  Free Report), Carnival (NYSE:(CCL - Free Report)  Free Report), T. Rowe Price (Nasdaq:(TROW - Free Report)  Free Report) and Novo Nordisk (NYSE:(NVO - Free Report)  Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Top Analyst Reports for Apple, Pfizer and Carnival

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple (Nasdaq:(AAPL - Free Report) Free Report), Pfizer (NYSE:(PFE - Free Report) Free Report) and Carnival (NYSE:(CCL - Free Report) Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Apple’s shares are up +39.5% in the year-to-date period, handily outperforming the S&P 500 (up +13.3%) and the Zacks Technology sector (up +20.7%). The Zacks analyst thinks Apple’s enriched product portfolio that now includes the new iPhones, Watch 3 and 4K TV will help the stock sustain momentum against S&P 500 going forward. This, along with the company's $1-billion investment for acquiring original content and its plan to break into film distribution market will further boost services’ revenues.

Additionally, foray into fast-growing technologies like AI & AR/VR are long-term growth catalysts. However, the new iPhone X at $999 is quite pricey, particularly for markets like China and India. Moreover, slight delay in launching the product as compared with iPhone 8 and 8 Plus, reflects supply chain issues. This can be a concern during the upcoming holiday season. Moreover, intensifying competition from cheaper Chinese handset-makers cannot be ignored.

(You canread the full research report on Apple here >>>).

Shares of Pfizer have underperformed the peer group as well as the broader market year to date (the stock is up +12.1% over this period vs. a +19.3% increase for the Zacks Large-Cap Pharmaceuticals industry and the +13.4% gain for the S&P 500 index). Pfizer has been working on strengthening its product portfolio through acquisitions and licensing deals. However, Pfizer continues to face headwinds in the form of genericization of key drugs, lost alliance revenues, pricing pressure and rising competition which is hurting the top-line.

Though Pfizer’s growing immuno-oncology portfolio offers strong potential, many of these assets are in early stage of development. Nonetheless, new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential.

(You can read the full research report on Pfizer here >>>).

Carnival’s shares have outpaced the Zacks Leisure and Recreation Services industry in the past year, gaining +51% vs. +38.6%. The Zacks analyst likes the addition of new ships to its fleet given burgeoning demand for cruise travel in 2017. Additionally, Carnival is well positioned for continued earnings growth, given the current strength in its bookings along with pricing trends for the year.

Notably, its brand building efforts together with other marketing activities are driving bookings. Its strategy of growing beyond familiar itineraries and capitalizing on fast growing markets is likely to further drive growth. Meanwhile, estimates have been stable lately ahead of its fiscal third quarter earnings release and the company has positive record of earnings surprises in recent quarters.

However, adverse forex translations, higher costs along with macroeconomic issues in key operating regions remain headwinds. A potential increase in fuel costs can also hamper its profitability. (You can read the full research report on Carnival here >>>).

Other noteworthy reports we are featuring today include T. Rowe Price (Nasdaq:(TROW - Free Report) Free Report) and Novo Nordisk (NYSE:(NVO - Free Report) Free Report).

4 Surprising Tech Stocks to Keep an Eye On

Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.

See Stocks Now>>

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.

Get the full Report on AAPL - FREE

Get the full Report on PFE - FREE

Get the full Report on CCL - FREE

Get the full Report on TROW - FREE

Get the full Report on NVO - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

More from Zacks Press Releases

You May Like